Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C37H67NO13 |
Molecular Weight | 733.9282 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 18 / 18 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@]1([H])[C@](C)([C@@]([H])([C@@]([H])(C)C(=O)[C@]([H])(C)C[C@](C)([C@@]([H])([C@@]([H])(C)[C@@]([H])([C@@]([H])(C)C(=O)O1)O[C@@]2([H])C[C@](C)([C@]([H])([C@]([H])(C)O2)O)OC)O[C@@]3([H])[C@@]([H])([C@]([H])(C[C@@]([H])(C)O3)N(C)C)O)O)O)O
InChI
InChIKey=ULGZDMOVFRHVEP-RWJQBGPGSA-N
InChI=1S/C37H67NO13/c1-14-25-37(10,45)30(41)20(4)27(39)18(2)16-35(8,44)32(51-34-28(40)24(38(11)12)15-19(3)47-34)21(5)29(22(6)33(43)49-25)50-26-17-36(9,46-13)31(42)23(7)48-26/h18-26,28-32,34,40-42,44-45H,14-17H2,1-13H3/t18-,19-,20+,21+,22-,23+,24+,25-,26+,28-,29+,30-,31+,32-,34+,35-,36-,37-/m1/s1
Molecular Formula | C37H67NO13 |
Molecular Weight | 733.9282 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 18 / 18 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdfhttp://www.przychodnia.pl/el/leki.php3?lek=628http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdfCurator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68015643
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/061621s039lbl.pdfhttp://www.przychodnia.pl/el/leki.php3?lek=628http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf
Curator's Comment:: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68015643
Erythromycin ethylsuccinate (E.E.S.®, ERY-PED®) is an ester of erythromycin base and succinic acid. It is suitable for oral administration. Erythromycin is a macrolide antibiotic, produced by Saccharopolyspora erythraea (formerly Streptomyces erythraeus). It acts primarily as a bacteriostatic agent. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. Erythromycin does not affect nucleic acid synthesis.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15808097http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050207s071lbl.pdf
Curator's Comment:: Information about erythromycin ethylsuccinate is unavailable.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2363135 |
14.0 nM [Kd] | ||
Target ID: CHEMBL2363135 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7023159 |
|||
Target ID: CHEMBL2363135 |
14.0 nM [Kd] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date7.9660802E10 |
|||
Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date7.9660802E10 |
|||
Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date7.9660802E10 |
|||
Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date7.9660802E10 |
|||
Curative | Erythromycin Approved UseErythromycin is indicated in the treatment of respiratory tract infections due to Mycoplasma pneumoniae; skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus; listeriosis caused by Listeria monocytogenes; diphtheria due to Corynebacterium diphtheriae infection, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers; erythrasma due to Corynebacterium minutissimum infection. Launch Date7.9660802E10 |
|||
Curative | Davercin Approved UseFor the topical treatment of acne vulgaris |
|||
Curative | Davercin Approved UseFor the topical treatment of pneumonia |
|||
Curative | Davercin Approved UseIndicated for the treatment of bacterial endocarditis |
|||
Curative | Davercin Approved UseUnknown |
|||
Curative | E.E.S. Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date-1.49990408E11 |
|||
Curative | E.E.S. Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date-1.49990408E11 |
|||
Curative | E.E.S Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date-1.49990408E11 |
|||
Curative | E.E.S. Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date-1.50076801E11 |
|||
Curative | E.E.S. Approved UseE.E.S. is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below:
Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H.influenzae are not susceptible to the erythromycin concentrations ordinarily achieved).
Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumonia or Streptococcus pyogenes.
Listeriosis caused by Listeria monocytogenes.
Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals.
Respiratory tract infections due to Mycoplasma pneumoniae.
Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment).
Diphtheria: Infections due to Corynebacterium diphtheria , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers.
Erythrasma: In the treatment of infections due to Corynebacterium minutissimum.
Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only).
Extraenteric amebiasis requires treatment with other agents.
Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N.gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months.
Syphilis caused by Treponema pallidum: Erythromycin is an alternate choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy.
Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis.
When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum.
Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Launch Date-1.50076801E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1.18 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2.44 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.62 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
250 mg 4 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1.99 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
250 mg 4 times / day multiple, oral dose: 250 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1161.5 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1386.1 ng/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
6.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6628511/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN serum | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
3544.7 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4096.7 ng × h/mL |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.48 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
5.31 h |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
ERYTHROMYCIN unknown | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
healthy, 12 years n = 1 Health Status: healthy Age Group: 12 years Sex: F Population Size: 1 Sources: |
Other AEs: Pancreatitis... |
5.3 g 1 times / day single, oral Studied dose Dose: 5.3 g, 1 times / day Route: oral Route: single Dose: 5.3 g, 1 times / day Sources: |
healthy, 15 years n = 1 Health Status: healthy Age Group: 15 years Sex: F Population Size: 1 Sources: |
Other AEs: Pancreatitis... |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 30 years n = 35 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 35 Sources: |
Disc. AE: Vomiting... AEs leading to discontinuation/dose reduction: Vomiting (2.8%) Sources: |
500 mg 3 times / day multiple, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: |
unhealthy, mean age 30 years n = 41 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 41 Sources: |
Disc. AE: Nausea, Abdominal pain... AEs leading to discontinuation/dose reduction: Nausea (14.6%) Sources: Abdominal pain (4.9%) |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 44 years n = 120 Health Status: unhealthy Condition: streptococcal pharyngitis Age Group: mean age 44 years Sex: M+F Population Size: 120 Sources: |
Disc. AE: Epigastralgia, Nausea... AEs leading to discontinuation/dose reduction: Epigastralgia (grade 2-3, 2.5%) Sources: Nausea (grade 3, 3.3%) Vomiting (grade 2, 0.8%) |
100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unhealthy n = 9 Health Status: unhealthy Condition: Parkinson's Disease Population Size: 9 Sources: |
Other AEs: Akathisia, Diarrhea... Other AEs: Akathisia (below serious, 1 patient) Sources: Diarrhea (below serious, 1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Pancreatitis | 5 g 1 times / day single, oral Studied dose Dose: 5 g, 1 times / day Route: oral Route: single Dose: 5 g, 1 times / day Sources: |
healthy, 12 years n = 1 Health Status: healthy Age Group: 12 years Sex: F Population Size: 1 Sources: |
|
Pancreatitis | 5.3 g 1 times / day single, oral Studied dose Dose: 5.3 g, 1 times / day Route: oral Route: single Dose: 5.3 g, 1 times / day Sources: |
healthy, 15 years n = 1 Health Status: healthy Age Group: 15 years Sex: F Population Size: 1 Sources: |
|
Vomiting | 2.8% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 30 years n = 35 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 35 Sources: |
Nausea | 14.6% Disc. AE |
500 mg 3 times / day multiple, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: |
unhealthy, mean age 30 years n = 41 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 41 Sources: |
Abdominal pain | 4.9% Disc. AE |
500 mg 3 times / day multiple, oral Recommended Dose: 500 mg, 3 times / day Route: oral Route: multiple Dose: 500 mg, 3 times / day Sources: |
unhealthy, mean age 30 years n = 41 Health Status: unhealthy Condition: maxillary sinusitis Age Group: mean age 30 years Sex: M+F Population Size: 41 Sources: |
Vomiting | grade 2, 0.8% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 44 years n = 120 Health Status: unhealthy Condition: streptococcal pharyngitis Age Group: mean age 44 years Sex: M+F Population Size: 120 Sources: |
Epigastralgia | grade 2-3, 2.5% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 44 years n = 120 Health Status: unhealthy Condition: streptococcal pharyngitis Age Group: mean age 44 years Sex: M+F Population Size: 120 Sources: |
Nausea | grade 3, 3.3% Disc. AE |
500 mg 2 times / day multiple, oral Recommended Dose: 500 mg, 2 times / day Route: oral Route: multiple Dose: 500 mg, 2 times / day Sources: |
unhealthy, mean age 44 years n = 120 Health Status: unhealthy Condition: streptococcal pharyngitis Age Group: mean age 44 years Sex: M+F Population Size: 120 Sources: |
Akathisia | below serious, 1 patient | 100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unhealthy n = 9 Health Status: unhealthy Condition: Parkinson's Disease Population Size: 9 Sources: |
Diarrhea | below serious, 1 patient | 100 mg single, intravenous Dose: 100 mg Route: intravenous Route: single Dose: 100 mg Sources: |
unhealthy n = 9 Health Status: unhealthy Condition: Parkinson's Disease Population Size: 9 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely | ||||
moderate [IC50 9.9 uM] | yes (co-administration study) Comment: Erythromycin increased mean Cmax value of simvastatin 3.4 fold and AUC0-24 value 6.2 fold; coadministered erythromycin has been reported to increase AUCs of simvastatin, triazolam, and midazolam 6.2-, 3.6-, and 3.8-fold, respectively; A significant increase in colchicine plasma concentration is anticipated when co-administered with moderate CYP3A4 inhibitors such as erythromycin; Page: 10.0 |
|||
yes [IC50 217 uM] | ||||
yes [IC50 22.7 uM] | ||||
yes [IC50 34 uM] |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes | ||||
yes | likely (co-administration study) Comment: Coadministration of erythromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/050207s074,050611s036lbl.pdf#page=9 Page: 9.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
The in-vitro activity of two new quinolones: rufloxacin and MF 961. | 1992 Jun |
|
[Bacteriostatic activity and killing curves of eight antibiotics against seven strains of penicillin G-resistant pneumococci]. | 1992 May |
|
[In vitro activity of sparfloxacin against mycoplasmas]. | 1992 May |
|
Treatment of experimental pneumocystosis: review of 7 years of experience and development of a new system for classifying antimicrobial drugs. | 1992 Sep |
|
Receptor for motilin identified in the human gastrointestinal system. | 1999 Jun 25 |
|
Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. The Azithromycin Intravenous Clinical Trials Group. | 2000 Jul |
|
Bone marrow engraftment: histopathology of hematopoietic reconstitution following allogeneic transplantation in CML patients. | 2001 Jan |
|
Insertion of H2C=CHX (X = F, Cl, Br, O(i)Pr) into (tBu3SiO)3TaH2 and beta-X-Elimination from (tBu3SiO)3HTaCH2CH2X (X = OR): relevance to Ziegler-Natta copolymerizations. | 2001 May 23 |
|
Early and delayed effects of carboplatin on the blood system. | 2001 Nov |
|
Stereochemistry of aldols: configuration and conformation of aldols derived from cycloalkanones and aldehydes. | 2001 Sep 19 |
|
Stereodivergent approach to beta-hydroxy alpha-amino acids from C(2)-symmetrical alk-2-yne-1,4-diols. | 2002 Dec 12 |
|
L-erythrulose production by oxidative fermentation is catalyzed by PQQ-containing membrane-bound dehydrogenase. | 2002 Feb |
|
Stereoselective binding of 2-(4-biphenylyl)-3-substituted-3-hydroxypropionic acids on an immobilised human serum albumin chiral stationary phase. | 2002 Feb 25 |
|
[Hormone level and metabolism of xenobiotics in rats with various phenotype of resistance to hypoxia]. | 2002 Jan-Feb |
|
Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. | 2002 Jul |
|
Dynamics of CD34+ progenitor cells following allogeneic bone marrow transplantation in Ph1+CML--an immunohistochemical study on 113 patients with sequential trephine biopsies. | 2002 Jun |
|
Erythro- and threo-2-hydroxynonyl substituted 2-phenyladenines and 2-phenyl-8-azaadenines: ligands for A1 adenosine receptors and adenosine deaminase. | 2002 Mar |
|
A density-functional study of the mechanism for the diastereoselective epoxidation of chiral allylic alcohols by the titanium peroxy complexes. | 2002 Mar 8 |
|
Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803. | 2002 Nov 1 |
|
Interaction of cytochrome P450 3A inhibitors with P-glycoprotein. | 2002 Oct |
|
Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. | 2002 Sep |
|
QT prolongation and torsades de pointes associated with concurrent use of cisapride and erythromycin. | 2002 Sep-Oct |
|
Massive venlafaxine overdose resulted in a false positive Abbott AxSYM urine immunoassay for phencyclidine. | 2003 |
|
Mixed chimerism of erythro- and megakaryopoiesis following allogeneic bone marrow transplantation. | 2003 |
|
Gamma-fluorinated analogues of glutamic acid and glutamine. | 2003 Apr |
|
[Postoperative ileus: part II (Clinical therapy)]. | 2003 Apr |
|
Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. | 2003 Feb 1 |
|
A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3% erythromycin/5% benzoyl peroxide and 0.025% tretinoin/erythromycin 4% in the treatment of moderate acne vulgaris of the face. | 2003 Jan-Feb |
|
A novel enzyme, D-3-hydroxyaspartate aldolase from Paracoccus denitrificans IFO 13301: purification, characterization, and gene cloning. | 2003 Jul |
|
Stereoselective biosynthesis of chloroarylpropane diols by the basidiomycete Bjerkandera adusta. | 2003 Jul |
|
Modifications to the N-terminus but not the C-terminus of calcitonin gene-related peptide(8-37) produce antagonists with increased affinity. | 2003 Jun 5 |
|
Systematic synthesis of Bis-THF ring cores in annonaceous acetogenins. | 2003 May 1 |
|
The relationship of physico-chemical properties and structure to the differential antiplasmodial activity of the cinchona alkaloids. | 2003 Sep 1 |
|
erythro-1-Naphthyl-1-(2-piperidyl)methanol: synthesis, resolution, NMR relative configuration, and VCD absolute configuration. | 2003 Sep 19 |
|
Bitterness evaluation of medicines for pediatric use by a taste sensor. | 2004 Aug |
|
Delayed Gastric Emptying in Functional Dyspepsia. | 2004 Aug |
|
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. | 2004 Dec |
|
Dicloxacillin and erythromycin at high concentrations increase ICAM-1 expression by endothelial cells: a possible factor in the pathogenesis of infusion phlebitis. | 2004 Feb |
|
[3 + 2] Cycloreversion of bicyclo[m.3.0]alkan-3-on-2-yl-1-oxonium ylides to alkenyloxyketenes. Stereospecific aspect. | 2004 Feb 20 |
|
Cytochrome P450/NADPH-dependent formation of trans epoxides from trans-arachidonic acids. | 2004 Feb 23 |
|
Conformational study of a guaiacyl beta-O-4 lignin model compound by NMR. Examination of intramolecular hydrogen bonding interactions and conformational flexibility in solution. | 2004 Mar |
|
Mechanism of beta-silyl diacyl peroxide decomposition: a mild and stereoselective synthesis of beta-silyl esters. | 2004 May 28 |
|
Effects of colchicine on the maximum biliary excretion of cholephilic compounds in rats. | 2004 Sep |
|
Initial (latent) polycythemia vera with thrombocytosis mimicking essential thrombocythemia. | 2005 |
|
Randomised controlled multiple treatment comparison to provide a cost-effectiveness rationale for the selection of antimicrobial therapy in acne. | 2005 Jan |
|
High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line. | 2005 Jan |
|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Cytotoxicity of neolignans identified in Saururus chinensis towards human cancer cell lines. | 2005 May |
|
Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). | 2005 May |
|
The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. | 2005 May |
Patents
Sample Use Guides
The usual dosage of erythromycin tablets is one 250 mg tablet four times daily in equally spaced doses or one 500 mg tablet every 12 hours. Dosage may be increased up to 4 g per day according to the severity of the infection. However, twice-a-day dosing is not recommended when doses larger than 1 g daily are administered.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:58:28 UTC 2021
by
admin
on
Fri Jun 25 20:58:28 UTC 2021
|
Record UNII |
63937KV33D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000007529
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
WHO-ATC |
S01AA17
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
WHO-ATC |
D10AF52
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
LIVERTOX |
367
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
WHO-ATC |
D10AF02
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
NDF-RT |
N0000175877
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
WHO-VATC |
QJ51RF02
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
6.2.2
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
CFR |
21 CFR 520.823
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
WHO-VATC |
QD10AF02
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
WHO-VATC |
QS01AA17
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
NDF-RT |
N0000007529
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
NDF-RT |
N0000009982
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
NCI_THESAURUS |
C261
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
WHO-VATC |
QJ01FA01
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
WHO-VATC |
QJ51FA01
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
NDF-RT |
N0000175935
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
WHO-ATC |
J01FA01
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
CFR |
21 CFR 522.820
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
CFR |
21 CFR 526.820
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
CFR |
21 CFR 556.230
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
CFR |
21 CFR 558.248
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
||
|
NDF-RT |
N0000007529
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2110577
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
CHEMBL532
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
12560
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
Erythromycin
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
1456
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
SUB06605MIG
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
3074
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
63937KV33D
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
1048
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
39
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
DB00199
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
4053
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | RxNorm | ||
|
ERYTHROMYCIN
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | Description: White or slightly yellow crystals or powder; odourless or almost odourless.Solubility: Soluble in 1000 parts of water but less soluble in hot water; freely soluble in ethanol (~750 g/l) TS and ether R.Category: Antibacterial drug.Storage: Erythromycin should be kept in a tightly closed container, protected from light.Additional information: Erythromycin is slightly hygroscopic.Definition: Erythromycin is a mixture of substances produced by the growth of certain strains of Streptomyces erythreus. The main component of the mixture is erythromycin A with lesser amounts of erythromycins B and C. | ||
|
114-07-8
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
ERYTHROMYCIN
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
M5009
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | Merck Index | ||
|
C476
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
114-07-8
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
1242000
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | USP-RS | ||
|
D004917
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY | |||
|
204-040-1
Created by
admin on Fri Jun 25 20:58:28 UTC 2021 , Edited by admin on Fri Jun 25 20:58:28 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
TRANSPORTER -> INHIBITOR | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
||
|
LABELED -> NON-LABELED | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SUBSTANCE->BASIS OF STRENGTH | |||
|
METABOLIC ENZYME -> INHIBITOR |
IC50
|
||
|
LABELED -> NON-LABELED | |||
|
METABOLIC ENZYME -> SUBSTRATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: ADULTS |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: S. PNEUMONIAE, S. PYOGENES |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: S. PNEUMONIAE, S. PYOGENES |
|
||
Tmax | PHARMACOKINETIC |
|
COMBINATION FORM: ERYTHROMYCIN ETHYLSUCCINATE |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: END-STAGE RENAL DISEASE |
|
||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: S. AUREUS |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: S. AUREUS |
|
||
Tmax | PHARMACOKINETIC |
|
FOOD EFFECT: DELAYED Tmax |
|
||
Tmax | PHARMACOKINETIC |
|
FOOD EFFECT: BASE |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: S. PNEUMONIAE, S. PYOGENES |
|
||
Biological Half-life | PHARMACOKINETIC |
|
POPULATION: NEONATES (LESS THAN OR EQUAL TO 15 DAYS OF AGE) |
|
||
MIC | BIOLOGICAL |
|
SUSCEPTIBILITY: S. AUREUS |
|
||